• MOLBREEVI* BLA PDUFA Target Action Date Set for November 22, 2026
  • MOLBREEVI MAAs Under Review by the EMA and the U.K.’s MHRA; Decisions Expected in Q1 2027 and Q4 2026, respectively
  • Data Presented at ATS Showed Molgramostim Demonstrated Continuous Long-term Improvements in Lung Function and Respiratory Health-Related Quality of Life
  • European and Australian Patent Offices Granted MOLBREEVI Liquid Formulation Patents, Providing Protection until March 2041